Pharmacokinetics of azithromycin and moxifloxacin in human conjunctiva and aqueous humor during and after the approved dosing regimens

American Journal of Ophthalmology

Volumn 150, Issue 5, 2010, Pages

  Stewart, William C ^a   Crean, Christopher S ^b   Zink, Richard C ^b   Brubaker, Kurt ^b   Haque, Reza M ^b   Hwang, David G ^c  

^a University of South Carolina   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; EYE DROPS; MOXIFLOXACIN; ANTIINFECTIVE AGENT; HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; AGED; AQUEOUS HUMOR; ARTICLE; BACTERIUM ISOLATE; CATARACT EXTRACTION; CLINICAL TRIAL; CONJUNCTIVA; CONJUNCTIVAL BIOPSY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HALF LIFE; FEMALE; GROWTH INHIBITION; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TANDEM MASS SPECTROMETRY; TREATMENT INDICATION; BIOAVAILABILITY; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AQUEOUS HUMOR; AZA COMPOUNDS; AZITHROMYCIN; BIOLOGICAL AVAILABILITY; CATARACT EXTRACTION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CONJUNCTIVA; FEMALE; FLUOROQUINOLONES; HALF-LIFE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; QUINOLINES; TANDEM MASS SPECTROMETRY;

EID: 78049482154     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2010.05.039     Document Type: Article

References (21)

1. Inspire Pharmaceuticals, Inc. AzaSite 2007 Inspire Pharmaceuticals, Inc Durham, NC [package insert]
2. E.K. Akpek, J. Vittitow, and R.S. Verhoeven Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation J Ocul Pharmacol Ther 25 5 2009 433 439
3. Alcon Laboratories, Inc. Vigamox 2003 Alcon Laboratories, Inc Fort Worth, TX [package insert]
4. M. Abelson, E. Protzko, A. Shapiro, A. Garces-Soldana, and L. Bowman A randomized trial assessing the clinical efficacy and microbial eradication of 1% azithromycin ophthalmic solution vs tobramycin in adult and pediatric subjects with bacterial conjunctivitis Clin Ophthalmol 1 2 2007 177 182
5. G.J. Hahn, and W.Q. Meeker Statistical Intervals: A Guide for Practitioners 1991 John Wiley & Sons New York
6. D.H. Peters, H.A. Friedel, and D. McTavish Azithromycin A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy Drugs 44 5 1992 750 799
7. M.B. Abelson, W. Heller, and A.M. Shapiro Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double masked clinical trial Am J Ophthalmol 145 6 2008 959 965
8. J.J. Kuehne, A.L. Yu, and G.N. Holland Corneal pharmacokinetics of topically applied azithromycin and clarithromycin Am J Ophthalmol 138 4 2004 547 553
9. S. Dey, S. Gunda, and A.K. Mitra Pharmacokinetics of erythromycin in rabbit corneas after single-dose infusion: role of P-glycoprotein as a barrier to in vivo ocular drug absorption J Pharmacol Exp Ther 311 1 2004 246 255
10. R.H. Gross, G.N. Holland, S.J. Elias, and R. Tuz Corneal pharmacokinetics of topical clarithromycin Invest Ophthalmol Vis Sci 36 5 1995 965 968
11. G. Torkildsen, and T.P. O'Brien Conjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers Clin Ther 30 11 2008 2005 2014
12. M. Aihara, M. Miyanaga, and K. Minami A comparison of fluoroquinolone penetration into human conjunctival tissue J Ocul Pharmacol Ther 24 6 2008 587 591
13. H.R. Katz, S. Masket, and S.S. Lane Absorption of topical moxifloxacin ophthalmic solution into human aqueous humor Cornea 24 8 2005 955 958
14. D.H. Kim, W.J. Stark, T.P. O'Brien, and J.D. Dick Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients Ophthalmology 112 11 2005 1992 1996
15. J.P. McCulley, D. Caudle, J.D. Aronowicz, and W.E. Shine Fourth-generation fluoroquinolone penetration into the aqueous humor in humans Ophthalmology 113 6 2006 955 959
16. W.W. Lai, K.O. Chu, and K.P. Chan Differential aqueous and vitreous concentrations of moxifloxacin and ofloxacin after topical administration one hour before vitrectomy Am J Ophthalmol 144 2 2007 315 318
17. E.J. Holland, S.S. Lane, T. Kim, M. Raizman, and S. Dunn Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty Cornea 27 3 2008 314 319
18. F. Crokaert, A. Hubloux, and P. Cauchie A phase I determination of azithromycin in plasma during a 6-week period in normal volunteers after a standard dose of 500 mg once daily for 3 days Clin Drug Investig 16 2 1998 161 166
19. T.J. Liesegang Intracameral antibiotics: questions for the United States based on prospective studies J Cataract Refract Surg 34 3 2008 505 509
20. M.G. Speaker, F.A. Milch, M.K. Shah, W. Eisner, and B.N. Kreiswirth Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis Ophthalmology 98 5 1991 639 650
21. H. Mio de Kaspar, T.C. Kreutzer, and I. Aguirre-Romo A prospective randomized study to determine the efficacy of preoperative topical levofloxacin in reducing conjunctival bacterial flora Am J Ophthalmol 145 1 2008 136 142